[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1124316T1 - Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα - Google Patents

Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Info

Publication number
CY1124316T1
CY1124316T1 CY20211100652T CY211100652T CY1124316T1 CY 1124316 T1 CY1124316 T1 CY 1124316T1 CY 20211100652 T CY20211100652 T CY 20211100652T CY 211100652 T CY211100652 T CY 211100652T CY 1124316 T1 CY1124316 T1 CY 1124316T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparations
pi3k delta
selective inhibitor
tosylate salt
crystalline tosylate
Prior art date
Application number
CY20211100652T
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of CY1124316T1 publication Critical patent/CY1124316T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μορφές στερεάς κατάστασης ενός άλατος p-τολουολοσουλφονικού οξέος (PTSA) του εκλεκτικού ΡΙ3Κ δέλτα αναστολέα (S)-2-(1-(4-αμινο-3-(3-φθορο-4-ισοπροποξυφαινυλ)-1Η-πυραζολο[3,4-d]πυριμιδιν-1-υλ)αιθυλ)-3-(3-φθορο-φαινυλ)-4Η-χρωμεν-4-όνη (TGR-1202). Η παρούσα εφεύρεση αφορά επίσης μεθόδους παρασκευής αυτών, φαρμακευτικές συνθέσεις που περιέχουν αυτές και μεθόδους θεραπείας μιας νόσου ή διαταραχής που διαμεσολαβείται από ΡΙ3Κ κινάση, όπως ο καρκίνος, δια της χορήγησης αυτών.
CY20211100652T 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα CY1124316T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1124316T1 true CY1124316T1 (el) 2022-07-22

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100652T CY1124316T1 (el) 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Country Status (21)

Country Link
US (4) US9969740B2 (el)
EP (2) EP3971188A1 (el)
JP (3) JP6987501B2 (el)
KR (1) KR20170007480A (el)
CN (2) CN106661030B (el)
AU (1) AU2015265542B2 (el)
BR (1) BR112016027674A2 (el)
CA (1) CA2949932C (el)
CY (1) CY1124316T1 (el)
DK (1) DK3149000T3 (el)
EA (1) EA032506B1 (el)
ES (1) ES2880999T3 (el)
HR (1) HRP20211151T1 (el)
HU (1) HUE054916T2 (el)
IL (1) IL249058B2 (el)
LT (1) LT3149000T (el)
PL (1) PL3149000T3 (el)
PT (1) PT3149000T (el)
RS (1) RS62136B1 (el)
SI (1) SI3149000T1 (el)
WO (1) WO2015181728A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032506B1 (ru) * 2014-05-27 2019-06-28 Ризен Фармасьютикалз Са Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF AN ANTI-CD20 ANTIBODY, A SELECTIVE P13 KINASE-DELTA INHIBITOR AND A BTK INHIBITOR FOR TREATING B LYMPHOCYTE PROLIFERATIVE DISORDERS
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
JP2022540466A (ja) 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522076A (en) * 2000-04-25 2005-08-26 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
NZ611764A (en) 2008-11-13 2015-01-30 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EA201101507A1 (ru) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
PL2870157T3 (pl) * 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektywne inhibitory pi3k delta
EA032506B1 (ru) * 2014-05-27 2019-06-28 Ризен Фармасьютикалз Са Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах

Also Published As

Publication number Publication date
WO2015181728A1 (en) 2015-12-03
US9969740B2 (en) 2018-05-15
EP3149000A1 (en) 2017-04-05
PT3149000T (pt) 2021-07-27
ES2880999T3 (es) 2021-11-26
EA201692255A1 (ru) 2017-04-28
HUE054916T2 (hu) 2021-10-28
IL249058A0 (en) 2017-01-31
US10414773B2 (en) 2019-09-17
JP6987501B2 (ja) 2022-01-05
EP3971188A1 (en) 2022-03-23
AU2015265542A1 (en) 2016-12-08
EP3149000B1 (en) 2021-06-30
US20210269446A1 (en) 2021-09-02
JP2022082680A (ja) 2022-06-02
US10947244B2 (en) 2021-03-16
SI3149000T1 (sl) 2021-09-30
CN106661030A (zh) 2017-05-10
KR20170007480A (ko) 2017-01-18
US20170121336A1 (en) 2017-05-04
IL249058B (en) 2022-11-01
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
JP2020122022A (ja) 2020-08-13
BR112016027674A2 (pt) 2017-08-15
IL249058B2 (en) 2023-03-01
JP2017516785A (ja) 2017-06-22
US20190382411A1 (en) 2019-12-19
HRP20211151T1 (hr) 2021-10-15
CN111635406A (zh) 2020-09-08
CA2949932C (en) 2021-08-10
RS62136B1 (sr) 2021-08-31
PL3149000T3 (pl) 2021-11-02
US20190016725A1 (en) 2019-01-17
DK3149000T3 (da) 2021-08-30
AU2015265542B2 (en) 2019-05-09
LT3149000T (lt) 2021-09-10
CA2949932A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
CY1124316T1 (el) Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич